Patents by Inventor Jean-Marie Schneider
Jean-Marie Schneider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11872206Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: GrantFiled: July 1, 2022Date of Patent: January 16, 2024Assignee: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Patent number: 11617735Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: GrantFiled: June 28, 2022Date of Patent: April 4, 2023Assignee: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Patent number: 11576890Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: GrantFiled: February 26, 2021Date of Patent: February 14, 2023Assignee: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Patent number: 11559509Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: GrantFiled: June 28, 2022Date of Patent: January 24, 2023Assignee: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Publication number: 20220409568Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: ApplicationFiled: June 28, 2022Publication date: December 29, 2022Applicant: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Publication number: 20220378736Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: ApplicationFiled: July 1, 2022Publication date: December 1, 2022Applicant: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Publication number: 20220362206Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: ApplicationFiled: June 28, 2022Publication date: November 17, 2022Applicant: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Publication number: 20210236455Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: ApplicationFiled: February 26, 2021Publication date: August 5, 2021Applicant: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Patent number: 10987337Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: GrantFiled: December 16, 2019Date of Patent: April 27, 2021Assignee: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Publication number: 20200206182Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: ApplicationFiled: December 16, 2019Publication date: July 2, 2020Inventors: Bradford C. SIPPY, Raymond SKWIERCZYNSKI, Jean-Marie SCHNEIDER, Simon H. DROUIN, Charles GUERIN
-
Patent number: 10059696Abstract: The present invention relates to a process for preparing (R)-5-(2-(benzylamino)ethyl)-1-(6,8-difluorochroman-3-yl)-1H-imidazole-2(3H)-thione, and pharmaceutically acceptable salts thereof, especially the hydrochloride salt. The invention also relates to a process for making intermediates useful in the formation of said compound, and to the intermediates, per se.Type: GrantFiled: February 23, 2016Date of Patent: August 28, 2018Assignee: Bial-Portela & CA, S.A.Inventors: Alexander Beliaev, Jorge Bruno Reis Wahnon, David Alexander Learmonth, Jonathan Madec, Jean-Marie Schneider, William Maton
-
Patent number: 9598350Abstract: The present patent application relates to a process for preparing cinacalcet or a pharmaceutically acceptable salt thereof, which comprises reacting 3-trifluoromethylbenzaldehyde having the following formula (II) with the phosphorus-comprising derivative having the following formula (III) in which R1 and R2, which may be identical or different, are each a (C1-C6)alkyl group. The present invention also relates to the phosphorus-comprising derivative having the formula (III), to the use thereof and to the process for preparing same. The present invention also relates to the phosphate salt of cinacalcet and to uses thereof.Type: GrantFiled: March 21, 2016Date of Patent: March 21, 2017Assignee: Produits Chimiques Auxiliaries et de SyntheseInventors: Jean-Marie Schneider, Jonathan Madec, Sergio Kreimerman, Gerard Guillamot
-
Patent number: 9487477Abstract: The present invention relates to a new crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and its use, particularly in the pharmaceutical industry, and to processes for preparation thereof. The invention is also directed to pharmaceutical compositions containing at least one crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and to the therapeutic or prophylactic use of such crystalline phase and compositions comprising the same.Type: GrantFiled: February 1, 2016Date of Patent: November 8, 2016Assignee: Quantum GenomicsInventors: Fabrice Balavoine, Jean-Marie Schneider, Gérard Coquerel, Nicolas Couvrat
-
Publication number: 20160311804Abstract: The present invention relates to a process for preparing (R)-5-(2-(benzylamino)ethyl)-1-(6,8-difluorochroman-3-yl)-1H-imidazole-2(3H)-thione, and pharmaceutically acceptable salts thereof, especially the hydrochloride salt. The invention also relates to a process for making intermediates useful in the formation of said compound, and to the intermediates, per se.Type: ApplicationFiled: February 23, 2016Publication date: October 27, 2016Inventors: Alexander BELIAEV, Jorge Bruno Reis WAHNON, David Alexander LEARMONTH, Jonathan MADEC, Jean-Marie SCHNEIDER, William MATON
-
Publication number: 20160221940Abstract: The present invention relates to a new crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and its use, particularly in the pharmaceutical industry, and to processes for preparation thereof. The invention is also directed to pharmaceutical compositions containing at least one crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and to the therapeutic or prophylactic use of such crystalline phase and compositions comprising the same.Type: ApplicationFiled: February 1, 2016Publication date: August 4, 2016Inventors: Fabrice Balavoine, Jean-Marie Schneider, Gérard Coquerel, Nicolas Couvrat
-
Publication number: 20160200664Abstract: The present patent application relates to a process for preparing cinacalcet or a pharmaceutically acceptable salt thereof, which comprises reacting 3-trifluoromethylbenzaldehyde having the following formula (II) with the phosphorus-comprising derivative having the following formula (III) in which R1 and R2, which may be identical or different, are each a (C1-C6)alkyl group. The present invention also relates to the phosphorus-comprising derivative having the formula (III), to the use thereof and to the process for preparing same. The present invention also relates to the phosphate salt of cinacalcet and to uses thereof.Type: ApplicationFiled: March 21, 2016Publication date: July 14, 2016Applicant: Produits Chimiques Auxiliaires et de SyntheseInventors: Jean-Marie Schneider, Jonathan Madec, Sergio Kreimerman, Gerard Guillamot
-
Patent number: 9346751Abstract: The present invention relates to a process for preparing (R)-5-(2-(benzylamino)ethyl)-1-(6,8-difluorochroman-3-yl)-1H-imidazole-2(3H)-thione, and pharmaceutically acceptable salts thereof, especially the hydrochloride salt. The invention also relates to a process for making intermediates useful in the formation of said compound, and to the intermediates, per se.Type: GrantFiled: June 29, 2012Date of Patent: May 24, 2016Assignee: Bial-Portela & CA, S.A.Inventors: Alexander Beliaev, Jorge Bruno Reis Wahnon, David Alexander Learmonth, Jonathan Madec, Jean-Marie Schneider, William Maton
-
Patent number: 9340497Abstract: The present invention relates to a new method for the preparation of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) in five steps from (S)-ethyl 2-(benzyloxycarbonylamino)-4-(neopentyloxysulfonyl)butanoate A.Type: GrantFiled: October 27, 2015Date of Patent: May 17, 2016Assignee: QUANTUM GENOMICSInventors: Fabrice Balavoine, Jonathan Madec, Jean-Marie Schneider, Gerard Coquerel, Nicolas Couvrat, Yohann Cartigny, Marie-Noelle Petit
-
Patent number: 9290439Abstract: The present patent application relates to a process for preparing, cinacalcet or a pharmaceutically acceptable salt thereof, which comprises reacting 3-trifluoromethylbenzaldehyde having the following formula (II) with the phosphorus-comprising derivative having the following formula (III) in which R1 and R2, which may be identical or different, are each a (C1-C6)alkyl group. The present invention also relates to the phosphorus-comprising derivative having the formula (III), to the use thereof and to the process for preparing same. The present invention also relates to the phosphate salt of cinacalcet and to uses thereof.Type: GrantFiled: September 9, 2013Date of Patent: March 22, 2016Assignee: Produits Chimiques Auxiliaires et de SyntheseInventors: Jean-Marie Schneider, Jonathan Madec, Sergio Kreimerman, Gerard Guillamot
-
Patent number: 9278921Abstract: The present invention relates to a new crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and its use, particularly in the pharmaceutical industry, and to processes for preparation thereof. The invention is also directed to pharmaceutical compositions containing at least one crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and to the therapeutic or prophylactic use of such crystalline phase and compositions comprising the same.Type: GrantFiled: October 22, 2013Date of Patent: March 8, 2016Assignee: Quantum GenomicsInventors: Fabrice Balavoine, Jean-Marie Schneider, Gérard Coquerel, Nicolas Couvrat